LENZ (LENZ Therapeutics) Operating Margin %: -2,321.67% (As of Mar. 2026)


LENZ LENZ Therapeutics Inc LENZ
12 GF Score
Price $5.51
! 2 Warning Signs
View Full Analysis

What is LENZ Therapeutics Operating Margin %?

LENZ Therapeutics LENZ -1.25% 12 Operating Margin % is -2,321.67% as of Mar. 2026. GuruFocus rates LENZ with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 944 Biotechnology companies, LENZ Therapeutics ranks worse than 71.4% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. LENZ Therapeutics's Operating Income for the three months ended in Mar. 2026 was $-44.14 Mil. LENZ Therapeutics's Revenue for the three months ended in Mar. 2026 was $1.90 Mil. Therefore, LENZ Therapeutics's Operating Margin % for the quarter that ended in Mar. 2026 was -2,321.67%.

The historical rank and industry rank for LENZ Therapeutics's Operating Margin % or its related term are showing as below:

LENZ' s Operating Margin % Range Over the Past 10 Years
Min: -563.83   Med: -273.68   Max: -69.89
Current: -563.83


LENZ's Operating Margin % is ranked worse than
71.4% of 944 companies
in the Biotechnology industry
Industry Median: -86.83 vs LENZ: -563.83

LENZ Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

LENZ Therapeutics's Operating Income for the three months ended in Mar. 2026 was $-44.14 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was $-118.34 Mil.


LENZ Therapeutics  (NAS:LENZ) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


LENZ Therapeutics Operating Margin % Related Terms


LENZ Therapeutics Operating Margin % Historical Data

* Premium members only.

The historical data trend for LENZ Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LENZ Therapeutics Operating Margin % Chart

LENZ Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
0.00 -69.89 0.00 0.00 -477.46

LENZ Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -337.14 -151.10 -2,422.10 -2,321.67

LENZ vs CNXU, CHRS, SLGL: Operating Margin % Comparison

For the Biotechnology subindustry, LENZ Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LENZ Therapeutics Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LENZ Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where LENZ Therapeutics's Operating Margin % falls into.


LENZ
12GF Score
LENZ Therapeutics Inc LENZ
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LENZ Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

LENZ Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-91.138 / 19.088
=-477.46 %

LENZ Therapeutics's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=-44.135 / 1.901
=-2,321.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -2,321.67% mean?
LENZ Therapeutics (LENZ) has a Operating Margin % of -2,321.67% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on LENZ Therapeutics and its competitors. According to the industry distribution chart, LENZ Therapeutics ranks #674 out of 944 companies in the Biotechnology industry, placing it in the top 71.4%.
Is LENZ Therapeutics' Operating Margin % too high?
LENZ Therapeutics' current Operating Margin % is -2,321.67%. Based on the distribution chart, LENZ Therapeutics ranks #674 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, LENZ Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LENZ Therapeutics' Operating Margin % compare to CNXU and CHRS?
According to the Biotechnology industry distribution chart, LENZ Therapeutics ranks #674 out of 944 companies for Operating Margin %. This places LENZ Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on LENZ Therapeutics and its competitors. LENZ Therapeutics's current Operating Margin % is -2,321.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LENZ Therapeutics stock overvalued right now?
LENZ Therapeutics (LENZ) has a current Operating Margin % of -2,321.67%. The current Operating Margin % is -2,321.67%. LENZ Therapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For LENZ Therapeutics (LENZ), the current Operating Margin % is -2,321.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LENZ Therapeutics Business Description

Address 201 Lomas Santa Fe Drive, Suite 300, Solana Beach, CA, USA, 92075
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
12GF Score

Get the complete analysis for LENZ

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.51
Price